Blog Author: Dr
Ozempic label, AccessFDA Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system, Frontiers in Public Health (2022) Gastrointestinal tolerability of onceweekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss, Diabetes, Obesity, and Metabolism (2021) Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss, JAMA Network (2023) Constipation, Penn State College Medicine Foods for constipation, Johns Hopkins Medicine Exercise therapy in patients with constipation: A systematic review and meta-analysis of randomized controlled trials, Scandinavian Journal of Gastroenterology (2019) Bowel retraining, National Library of Medicine (2022) Concerned about constipation
If youre on the lighter side, you might not need as much to get the benefits
Lifestyle Factors Lifestyle choices, including diet and exercise, play significant roles in how quickly you see results from semaglutide
Ozempic, also known as Wegovy, was originally intended to treat type 2 diabetes
